Page 44 - Acrobat J Trad-21-3-2566

J Thai Trad Alt Med Vol. 21 No. 3 Sep-Dec 2023 527

ที่ 10 ไม่แตกต่างกันเมื่อเปรียบเทียบทั้ง 3 กลุ่ม และไม่มีการเปลี่ยนระดับความรุนแรงทางคลินิก
ข้อสรุปและข้อเสนอแนะ: ผงบดสมุนไพรฟ้าทะลายโจร ทั้งจากส่วนเหนือดินและจากเฉพาะส่วนของใบ
ให้ผลในการรักษาโควิด-19 ไม่แตกต่างจากยาฟาวิพิราเวียร์ แต่ฟ้าทะลายโจรหาง่ายและมีราคาถูกกว่า งานวิจัยนี้
จึงเสนอแนะในการรักษาโควิด-19 ที่มีอาการน้อยควรเลือกใช้ฟ้าทะลายโจรเป็นยาล�าดับแรกเมื่อเทียบกับ
ฟาวิพิราเวียร์
ค�ำส�ำคัญ: ฟ้าทะลายโจร, ฟาวิพิราเวียร์, โควิด-19, แอนโดรกราโฟไลด์

Randomized-Controlled Trial to Compare the Efficacy of Andrographis
paniculata Powder and Favipiravir for the Treatment of Mild COVID-19

Sirada Puriwatthanapong , Sant Chaiyodsilp , Thammarat Bunsoong , Paul Chaiyodsilp , Yathip
†
*,§
‡
†
Tipasaharn , Kamik Kulmanote , Methi Sicharoen , Wasini Mekvitoon , Chompunuch Settapol ,
*
*
*
*
*
Jariya Songrak , Kobkaew Burapha , Wirawan Polchan , Cholpatsorn Euathanikkanon ,
*
†
*
*
Jate Wantang ‡
* Muaklek Hospital, Mitrapap Sub-District, Muak Lek District, Saraburi 18180 Thailand
† Wellness We Care Center, Mitrapap Sub-District, Muak Lek District, Saraburi 18180 Thailand
‡ Regional Medical Service Center 4, Department of Medical Service, Ministry of Public Health, Mitrapap Sub-District,
Muak Lek District, Saraburi 18180 Thailand
Corresponding author: sirada.pur@gmail.com
§
Abstract
Introduction and Objective: This study sought to determine the effectiveness of the Andrographosis
paniculata (fa thalai chon in Thai) herb, in ground-powder form, in the treatment of COVID-19 compared to fa-
vipiravir, which is the current standard treatment regimen in Thailand.
Methods: The study was a randomized controlled trial in subjects aged 18 to under 60 years, who were
diagnosed with COVID-19 by a positive RT-PCR test and were recruited from Muaklek Hospital from October
2021 to April 2022 classified as having mild disease. Patients were block randomized into three treatment groups.
The first group was treated with ground powder of the aerial parts of A. paniculata (400 mg per capsule containing
11.35 mg of andrographolide) 180 mg/day for 5 days. The second group was treated with ground A. paniculata
leaves (400 mg per capsule containing 24 mg of andrographolide) 180 mg/day for 5 days. The third group was
treated with favipiravir at a dose of 3,600 mg on day 1 and 1,600 mg/day on days 2 to 5. Patients were followed up
for 10 days, with worsening of clinical severity indicated by change in color category, new pulmonary infiltrations
on x-ray, and viral load reduction on days 0, 5 and 10 as the primary outcomes.
Results: All 231 subjects were recruited to the study, with 77 assigned to each group. None of the groups
had worsening of clinical severity indicated by change in color category. The difference in new pulmonary infiltra-
tions between the groups was not statistically significant (p = 0.07), nor was the elevation in liver enzymes (p =
0.7). Viral loaded reduction did not differ significantly between each group. Log reduction on day 10 was 3.943
± 1.354 in the first group, 3.943 ± 1.414 in the second group, and 3.994 ± 1.284 in the third group, which also
showed no significant difference (p = 0.996).
Discussion: The efficacy of ground powder of both aerial parts and leaves of A. paniculata was not sig-